Table 1. Baseline demographic and clinical characteristics of the subset of women with previously treated hormone receptor-negative breast cancer, participating in a Polyphenon E (Poly E) intervention study, and evaluable for biomarker analyses (n = 34).
| Characteristics | Poly E (n = 26) | Placebo (n = 8) | Total (n = 34) |
|---|---|---|---|
| Median age, years (range) | 54.5 (39–65) | 56.5 (47–61) | 55 (39–65) |
| Menopausal status, n (%) | |||
| Premenopausal | 5 (19) | 2 (25) | 7 (21) |
| Post-menopausal | 21 (81) | 6 (75) | 27 (79) |
| Race, n (%) | |||
| White | 15 (58) | 5 (63) | 20 (59) |
| Hispanic | 5 (19) | 2 (25) | 7 (20) |
| Black | 5 (19) | 1 (12) | 6 (18) |
| Asian | 1 (4) | 0 (0) | 1 (3) |
| Median body mass index (kg m−2) (range) | 28 (21–41) | 29 (23–34) | 29 (21–41) |
| Stage, n (%) | |||
| I | 13 (50) | 2 (25) | 15 (44) |
| II | 7 (27) | 4 (50) | 11 (32) |
| III | 6 (23) | 2 (25) | 8 (24) |
| Breast cancer treatments, n (%) | |||
| Chemotherapy | 23 (88) | 7 (88) | 30 (88) |
| Trastuzumab | 4 (15) | 3 (38) | 7 (21) |
| Radiation therapy | 19 (73) | 7 (88) | 26 (76) |
| Median time since diagnosis, months (range) | 31 (10–170) | 40 (17–73) | 34 (10–170) |
| Dose level of Poly E, n (%) | |||
| 400 mg bid | 14 (54) | – | |
| 600 mg bid | 11 (42) | – | |
| 800 mg bid | 1 (4) | – | |